Galectin Therapeutics (GALT) Stock Price, News & Analysis

Company Overview

Galectin Therapeutics Inc. (NASDAQ:GALT) is a biotechnology company focused on developing therapies that target galectin-3, a protein believed to play a role in fibrosis, inflammation and cancer biology. The company’s research is aimed at addressing serious chronic diseases for which treatment options remain limited.

Galectin Therapeutics’ lead investigational product is belapectin, also known as GR-MD-02. The drug is designed to inhibit galectin-3 and has been studied primarily in patients with advanced liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension. Belapectin is an investigational therapy and has not received regulatory approval.

The company is also evaluating the potential use of galectin-3 inhibition in oncology, including as part of combination approaches intended to improve immune responses against cancer. Galectin Therapeutics was formerly known as Pro-Pharmaceuticals and adopted its current name in 2011. The company is headquartered in Norcross, Georgia, and conducts development activities through clinical research programs; specific commercial geographies are not applicable while its primary product remains investigational.

Key Stats

• Today's Range: $3.19 to $3.51
• 50-Day Range: $3.37 to $4.61
• 52-Week Range: $2.03 to $7.13
• Volume: 295,684 shs
• Average Volume: 203,132 shs
• Market Capitalization: $221.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Hold

Galectin Therapeutics Stock Analysis - MarketRank™

Galectin Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 747th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Galectin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Galectin Therapeutics has a consensus price target of $11.00, representing about 226.4% upside from its current price of $3.37.

Amount of Analyst Coverage

Galectin Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Galectin Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.23) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.49% of the float of Galectin Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Galectin Therapeutics has a short interest ratio ("days to cover") of 33.66, which indicates bearish sentiment.

Change versus previous month

Short interest in Galectin Therapeutics has recently decreased by 1.38%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galectin Therapeutics does not currently pay a dividend.

Dividend Growth

Galectin Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Galectin Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galectin Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

53.00% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.68% of the stock of Galectin Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/21/2026
• Next Earnings (Estimated): 11/13/2026
• AGM 2026: 12/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GALT
• CIK: 1133416
• Web: www.galectintherapeutics.com
• Phone: (678) 620-3186
• Fax: 770-864-1327
• Employees: 9
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Galectin Therapeutics: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +226.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -176.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.10
• Quick Ratio: 0.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.99) per share
• Price / Book: -1.69

Miscellaneous

• Outstanding Shares: 65,860,000
• Free Float: 30,953,000
• Market Cap: $221.95 million
• Optionable: Optionable
• Beta: 0.38